The treatment of premenstrual dysphoric disorder (PMDD) is far from satisfactory, as there is a high proportion of patients who do not respond to conventional treatment. The antidiuretic sulfonamide, acetazolamide, inhibits carbonic anhydrase and potentiates GABAergic transmission; the latter is putatively involved in PMDD. We therefore tried acetazolamide in a series of women with intractable PMDD. Here, we describe a series of eight women diagnosed with DSM-IV-TR PMDD, five of whom had comorbidity with a mood disorder and one with an anxiety disorder, who were resistant to treatment and responded with symptom disappearance after being added-on 125 mg/day acetazolamide for 7-10 days prior to menses each month. Patients were free from premenstrual symptoms at the 12-month follow-up. We suggest that acetazolamide may be used to improve symptoms of PMDD in cases not responding to other treatments. GABAergic mechanisms may be involved in counteracting PMDD symptoms.
The treatment of premenstrual dysphoric disorder (PMDD) is far from satisfactory, as there is a high proportion of patients who do not respond to conventional treatment. The antidiuretic sulfonamide, acetazolamide, inhibits carbonic anhydrase and potentiates GABAergic transmission; the latter is putatively involved in PMDD. We therefore tried acetazolamide in a series of women with intractable PMDD. Here, we describe a series of eight women diagnosed with DSM-IV-TR PMDD, five of whom had comorbidity with a mood disorder and one with an anxiety disorder, who were resistant to treatment and responded with symptom disappearance after being added-on 125 mg/day acetazolamide for 7-10 days prior to menses each month. Patients were free from premenstrual symptoms at the 12-month follow-up. We suggest that acetazolamide may be used to improve symptoms of PMDD in cases not responding to other treatments. GABAergic mechanisms may be involved in counteracting PMDD symptoms.
Low-dose acetazolamide in the treatment of premenstrual dysphoric disorder: a case series / Sani, Gabriele; Kotzalidis, Georgios; Panaccione, Isabella; Simonetti, Alessio; DE CHIARA, Lavinia; DEL CASALE, Antonio; Ambrosi, Elisa; Napoletano, Flavia; Janiri, Delfina; Emanuela, Danese; Girardi, Nicoletta; Rapinesi, Chiara; Serata, Daniele; Giovanni, Manfredi; Koukopoulos, Alexia; Angeletti, Gloria; Nicoletti, Ferdinando; Girardi, Paolo. - In: PSYCHIATRY INVESTIGATION. - ISSN 1738-3684. - 11:1(2014), pp. 95-101. [10.4306/pi.2014.11.1.95]
Low-dose acetazolamide in the treatment of premenstrual dysphoric disorder: a case series.
SANI, Gabriele;KOTZALIDIS, GEORGIOS;PANACCIONE, ISABELLA;SIMONETTI, ALESSIO;DE CHIARA, LAVINIA;DEL CASALE, ANTONIO;AMBROSI, ELISA;NAPOLETANO, FLAVIA;Delfina Janiri;GIRARDI, NICOLETTA;RAPINESI, CHIARA;SERATA, DANIELE;KOUKOPOULOS, ALEXIA;ANGELETTI, Gloria;NICOLETTI, Ferdinando;GIRARDI, Paolo
2014
Abstract
The treatment of premenstrual dysphoric disorder (PMDD) is far from satisfactory, as there is a high proportion of patients who do not respond to conventional treatment. The antidiuretic sulfonamide, acetazolamide, inhibits carbonic anhydrase and potentiates GABAergic transmission; the latter is putatively involved in PMDD. We therefore tried acetazolamide in a series of women with intractable PMDD. Here, we describe a series of eight women diagnosed with DSM-IV-TR PMDD, five of whom had comorbidity with a mood disorder and one with an anxiety disorder, who were resistant to treatment and responded with symptom disappearance after being added-on 125 mg/day acetazolamide for 7-10 days prior to menses each month. Patients were free from premenstrual symptoms at the 12-month follow-up. We suggest that acetazolamide may be used to improve symptoms of PMDD in cases not responding to other treatments. GABAergic mechanisms may be involved in counteracting PMDD symptoms.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
